The global hemophilia treatment drugs market was noted at a valuation of US$ 10,000.0 mn in 2017. Owing to increasing FDA approval to new patents, the market is expected to rise at a CAGR of 5.0% from 2019 to 2026. Increase in R&D investment by key players for developing new drugs for the treatment of hemophilia and rise in demand for long-acting replacement therapies and non-factor therapies are anticipated to fuel the growth of the global market during the forecast period. North America dominated the global market in 2017 owing to the introduction and uptake of new long-acting factors and alternative coagulation promoters and increase in the rate of diagnosis for hemophilia.
The report analyzes and forecasts the hemophilia treatment drugs market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of hemophilia treatment drugs, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major hemophilia treatment drugs companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of hemophilia treatment drugs upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of hemophilia treatment drugs and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global hemophilia treatment drugs market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the hemophilia treatment drugs market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of hemophilia treatment drugs market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
The report also profiles the major players in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in the hemophilia treatment drugs market include Pfizer, Inc., CSL Behring, Kedrion, Shire Plc., Novo Nordisk A/S, Bayer AG, F. Hoffmann-La Roche Ltd., and Sanofi.
Strategic collaboration agreements and new product development was the primary strategy adopted by major market players to bolster their position in the hemophilia treatment drugs market.
Report Segmentation:
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Hemophilia Market, By Type
7.1. Hemophilia Market, By Type, 2020-2030
7.1.1. Hemophilia A
7.1.1.1. Market Revenue and Forecast (2016-2030)
7.1.2. Hemophilia B
7.1.2.1. Market Revenue and Forecast (2016-2030)
7.1.3. Hemophilia C
7.1.3.1. Market Revenue and Forecast (2016-2030
7.1.4. Others
7.1.4.1. Market Revenue and Forecast (2016-2030)
Chapter 8. Global Hemophilia Market, By Treatment
8.1. Hemophilia Market, By Treatment, 2020-2030
8.1.1. On-demand
8.1.1.1. Market Revenue and Forecast (2016-2030)
8.1.2. Prophylaxis
8.1.2.1. Market Revenue and Forecast (2016-2030)
Chapter 9. Global Hemophilia Market, By Therapy
9.1. Hemophilia Market, By Therapy, 2020-2030
9.1.1. Replacement therapy
9.1.1.1. Market Revenue and Forecast (2016-2030)
9.1.2. ITI therapy
9.1.2.1. Market Revenue and Forecast (2016-2030)
9.1.3. Gene therapy
9.1.3.1. Market Revenue and Forecast (2016-2030)
Chapter 10. Global Hemophilia Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, By Type (2016-2030)
10.1.2. Market Revenue and Forecast, By Treatment (2016-2030)
10.1.3. Market Revenue and Forecast, By Therapy (2016-2030)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, By Type (2016-2030)
10.1.4.2. Market Revenue and Forecast, By Treatment (2016-2030)
10.1.4.3. Market Revenue and Forecast, By Therapy (2016-2030)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, By Type (2016-2030)
10.1.5.2. Market Revenue and Forecast, By Treatment (2016-2030)
10.1.5.3. Market Revenue and Forecast, By Therapy (2016-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, By Type (2016-2030)
10.2.2. Market Revenue and Forecast, By Treatment (2016-2030)
10.2.3. Market Revenue and Forecast, By Therapy (2016-2030)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, By Type (2016-2030)
10.2.4.2. Market Revenue and Forecast, By Treatment (2016-2030)
10.2.4.3. Market Revenue and Forecast, By Therapy (2016-2030)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, By Type (2016-2030)
10.2.5.2. Market Revenue and Forecast, By Treatment (2016-2030)
10.2.5.3. Market Revenue and Forecast, By Therapy (2016-2030)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, By Type (2016-2030)
10.2.6.2. Market Revenue and Forecast, By Treatment (2016-2030)
10.2.6.3. Market Revenue and Forecast, By Therapy (2016-2030)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, By Type (2016-2030)
10.2.7.2. Market Revenue and Forecast, By Treatment (2016-2030)
10.2.7.3. Market Revenue and Forecast, By Therapy (2016-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, By Type (2016-2030)
10.3.2. Market Revenue and Forecast, By Treatment (2016-2030)
10.3.3. Market Revenue and Forecast, By Therapy (2016-2030)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, By Type (2016-2030)
10.3.4.2. Market Revenue and Forecast, By Treatment (2016-2030)
10.3.4.3. Market Revenue and Forecast, By Therapy (2016-2030)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, By Type (2016-2030)
10.3.5.2. Market Revenue and Forecast, By Treatment (2016-2030)
10.3.5.3. Market Revenue and Forecast, By Therapy (2016-2030)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, By Type (2016-2030)
10.3.6.2. Market Revenue and Forecast, By Treatment (2016-2030)
10.3.6.3. Market Revenue and Forecast, By Therapy (2016-2030)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, By Type (2016-2030)
10.3.7.2. Market Revenue and Forecast, By Treatment (2016-2030)
10.3.7.3. Market Revenue and Forecast, By Therapy (2016-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, By Type (2016-2030)
10.4.2. Market Revenue and Forecast, By Treatment (2016-2030)
10.4.3. Market Revenue and Forecast, By Therapy (2016-2030)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, By Type (2016-2030)
10.4.4.2. Market Revenue and Forecast, By Treatment (2016-2030)
10.4.4.3. Market Revenue and Forecast, By Therapy (2016-2030)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, By Type (2016-2030)
10.4.5.2. Market Revenue and Forecast, By Treatment (2016-2030)
10.4.5.3. Market Revenue and Forecast, By Therapy (2016-2030)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, By Type (2016-2030)
10.4.6.2. Market Revenue and Forecast, By Treatment (2016-2030)
10.4.6.3. Market Revenue and Forecast, By Therapy (2016-2030)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, By Type (2016-2030)
10.4.7.2. Market Revenue and Forecast, By Treatment (2016-2030)
10.4.7.3. Market Revenue and Forecast, By Therapy (2016-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, By Type (2016-2030)
10.5.2. Market Revenue and Forecast, By Treatment (2016-2030)
10.5.3. Market Revenue and Forecast, By Therapy (2016-2030)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, By Type (2016-2030)
10.5.4.2. Market Revenue and Forecast, By Treatment (2016-2030)
10.5.4.3. Market Revenue and Forecast, By Therapy (2016-2030)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, By Type (2016-2030)
10.5.5.2. Market Revenue and Forecast, By Treatment (2016-2030)
10.5.5.3. Market Revenue and Forecast, By Therapy (2016-2030)
Chapter 11. Company Profiles
11.1. Shire (Baxalta)
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. CSL Behring
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Pfizer, Inc.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Bayer AG
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. BioMarin
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Spark Therapeutics, Inc.
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Genzyme Corporation
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Chugai Pharmaceutical Co. Ltd
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Novo Nordisk A/S
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Octapharma AG
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers